Archives of Virology

, Volume 157, Issue 10, pp 1959–1965 | Cite as

Molecular epidemiology of hepatitis C virus among injection drug users in Iran: a slight change in prevalence of HCV genotypes over time

  • Katayoun Samimi-RadEmail author
  • Mohsen Nasiri Toosi
  • Ali Masoudi-nejad
  • Ali Najafi
  • Ramin Rahimnia
  • Fatemeh Asgari
  • Alireza Namazi Shabestari
  • Gholamreza Hassanpour
  • Seyed-Moayed Alavian
  • Freshteh Asgari
Brief Report


Injecting drug users (IDUs) are the main at-risk population for hepatitis C virus (HCV) transmission. We studied HCV infection, risk factors, and genotype distribution in relation to the year of first injection among Iranian IDUs. Of a total of 126 specimens positive for HCV antibody, 93 (74 %) had detectible HCV RNA, and the NS5B gene was sequenced for 83, with genotype 3a (n = 48, 58 %) being predominant, followed by 1a (n = 35, 42 %). Tattooing was an independent predictor for HCV infection. No significant difference was found between HCV genotypes and IDU characteristics. Although there was no change in the distribution of prevalent genotypes before and after 1997, a slight variation in the prevalence was observed (p = 0.71). The difference in the prevalence of subtypes 1a and 3a (9.1 % in the period 1984-1996 and 18.2 % in the period 1997-2009) during 25 years was 9.1 %. These findings indicate a high prevalence of HCV infection among Iranian IDUs and highlights HCV-3a as the most prevalent subtype for the past 25 years. Harm-reduction strategies appear to be the most important measures to reduce the transmission of HCV in Iran.


Thalassemia Syringe Sharing Iranian IDUs Average Evolutionary Distance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



We would like to thank Dr. Ali Malakzadeh and his colleagues at West Health Center for their cooperation in sample collection. We thank Dr. Mehrdad Pedram (Dept. of Biotechnology and Medical Genetics, Zanjan University of Medical Sciences) for his careful editing of the manuscript and helpful comments.


  1. 1.
    Rezvan H, Abolghassemi H, Kafiabad SA (2007) Transfusion-transmitted infections among multitransfused patients in Iran: a review. Transfusion Med 17:425–433CrossRefGoogle Scholar
  2. 2.
    Zamani S, Radfar R, Nematollahi P, Fadaie R, Meshkati M, Mortazavi S, Sedaghat A, Ono-Kihara M, Kihara M (2010) Prevalence of HCV /HIV /HBV infections and drug–related risk behaviours amongst IDUs recruited through peer–driven sampling in Iran. Int J Drug policy 21:493–500PubMedCrossRefGoogle Scholar
  3. 3.
    Kheirandish P, Seyed Alinaghi S, Jahani M, Shirzad H, Seyed Ahmadian M, Majidi A, Sharifi A, Hosseini M, Mohraz M, McFarland W (2009) Prevalence and correlates of hepatitis C infection among male injection drug users in detention, Tehran, Iran. J Urban Health 86:902–908PubMedCrossRefGoogle Scholar
  4. 4.
    Zali MR, Nowroozi A, Amir-rasooly H, Darvishi M (1998) Prevalence of anti HCV antibody and routes of hematological transmission addicts of Ghasr prison [in Persian]. Pajouhesh 22:26–32Google Scholar
  5. 5.
    Zamani S, Ichikawa S, Nassiri manesh B, Vazirian M, Ichikawa K, Gouya MM, Afshar P, Ono-Kihara M, Mortazavi Ravari S, Kihara M (2007) Prevalence and correlates of HCV infection among injecting drug users in Tehran. Int J Drug policy 18:359–363PubMedCrossRefGoogle Scholar
  6. 6.
    Mohamad Alizadeh AH, Alavian SM, Jafari K, Yazdi N (2005) Prevalence of HCV infection and its related risk factors in drug abuser prisoners in Hamedan –Iran. World J Gastroenterol 11:4085–4089Google Scholar
  7. 7.
    Asgari F, Gooya MM, Mohammad K, Fotouhi A, Yousefi A (2008) Hepatitis C virus infection among Iranian prisoners and its relation with addiction, 2001–2005 [in Persian]. Hakim 11:1–8Google Scholar
  8. 8.
    Khani M, Vakili M-M (2003) Prevalence and risk factors of HIV, Hepatitis B virus and Hepatitis C virus infections in Drug addicts among Zanjan prisoners. Arch Iranian Med 6:1–4Google Scholar
  9. 9.
    Rowhani Rahbar A, Rooholamini S, Khoshnood K (2004) Prevalence of HIV infection and other blood borne infections in incarcerated and non-incarcerated injection drug users IVDUs in Mashhad. Iran. Int J Drug Policy 15:151–155CrossRefGoogle Scholar
  10. 10.
    Mohtasham Amiri Z, Rezvani M, Jafari shakib R, Jafari shakib A (2007) Prevalence of HCV infection and risk factors of drug using prisoners in Guilan province. EMHJ 13:250–256Google Scholar
  11. 11.
    Micalessi MI, Gerard C, Ameye L, Palasschaert B, Brochier B, Vranckx R (2008) Distribution of hepatitis C virus genotypes among injecting drug users in contact with treatment centers in Belgium, 2004–2005. J Med Virol 80:640–645PubMedCrossRefGoogle Scholar
  12. 12.
    Dal Molin G, Ansaldi F, Biagi C, D′Agro P, Comar M, Croce L, Tiribelli C, Campello C (2002) Changing molecular epidemiology of hepatitis C virus infection in Northeast Italy. J Med Virol 68:352–356PubMedCrossRefGoogle Scholar
  13. 13.
    Samimi-Rad K, Shahbaz B (2007) Hepatitis C virus genotypes among patients with thalassemia and inherited bleeding disorders in Markazi province. Iran. Haemophilia 13:156–163CrossRefGoogle Scholar
  14. 14.
    Hosseini-Moghaddam SM, Keyvani H, Kasiri H, Kazemeyni SM, Basiri A, Aghel N, Alavian SM (2006) Distribution of hepatitis C virus genotypes among hemodialysis patients in Tehran–a multicenter study. J Med Virol 78:569–573PubMedCrossRefGoogle Scholar
  15. 15.
    Alavian SM, Miri SM, Keshvari M, Elizee PK, Behnava B, Tabatabaei SV, Lankarani KB (2009) Distribution of hepatitis C virus genotype in Iranian multiply transfused patients with thalassemia. Transfusion 49:2195–2199PubMedCrossRefGoogle Scholar
  16. 16.
    Samimi-Rad K, Nategh R, Malekzadeh R, Norder H, Magnius L (2004) Molecular of epidemiology of Hepatitis C virus in Iran as reflected by phylogenetic analysis of the NS5B region. J Med Virol 74:246–252PubMedCrossRefGoogle Scholar
  17. 17.
    Kimura M (1980) A simple method for estimating evolutionary rate of base substitutions through comparative studies of nucleotide sequences. J Mol Evol 16:111–120PubMedCrossRefGoogle Scholar
  18. 18.
    Sereno S, Perinelli P, Laghi V (2009) Changes in the prevalence of hepatitis C virus genotype among Italian injection drug users-relation to period of injection started. J Clin Virol 45:354–357PubMedCrossRefGoogle Scholar
  19. 19.
    Kabir A, Alavian SM, Keyvani H (2006) Distribution of hepatitis C virus genotypes in patients infected by different sources and its correlation with clinical and virological parameters: a preliminary study. Comp Hepatol 5:4PubMedCrossRefGoogle Scholar
  20. 20.
    Paintsil E, Verevochkin SV, Dukhovlinova E, Niccolai L, Barbour R, White E, Toussova OV, Alexander L, Kozlov AP, Heimer R (2009) Hepatitis C virus infection among drug injectors in St. Petersburg, Russia: social and molecular epidemiology of an endemic infection. NIH 104:1881–1890Google Scholar
  21. 21.
    Demetriou VL, van de Vijver DA, Hezka J, Kostrikis LG; Cyprus IVDU Network, Kostrikis LG (2010) Hepatitis C infection among intravenous drug users attending therapy programs in Cyprus. J Med Virol 82:263–270Google Scholar
  22. 22.
    Abolghassemi H, Amid A, Zeinali S, Radfar MH, Eshghi P, Rahiminejad MS, Ehsani MA, Najmabadi H, Akbari MT, Afrasiabi A, Akhavan-Niaki H, Hoorfar H (2007) Thalassemia in Iran: epidemiology, prevention, and management. J Pediat Hematol Onc 29:233–238CrossRefGoogle Scholar
  23. 23.
    Zali MR, Aghazadeh R, Noroozi A, Amirrasooli H (2001) Anti-HCV antibody among Iranian IV drug users: is it a serious problem? Arch Iranian Med 4:115–119Google Scholar
  24. 24.
    Hickman M, Hope V, Brady T, Madden P, Jones S, Honor S, Holloway G, Ncube F, Parry J (2007) Hepatitis C virus (HCV) prevalence and injecting risk behaviour in multiple sites in England in 2004. J Viral Hepatitis 14:645–652CrossRefGoogle Scholar
  25. 25.
    Esteban J, Sauleda S, Quer J (2008) The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 48:148–162PubMedCrossRefGoogle Scholar
  26. 26.
    Kalilina O, Norder H, Vetrov T, Zhdanov K, Barzunova M, Plotnikova V, Mukomolov S, Magnius LO (2001) Shift in predominating subtype of HCV from 1b to 3a in St. Petersburg mediated by increase in injecting drug use. J Med Virol 65:517–524CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Katayoun Samimi-Rad
    • 1
    Email author
  • Mohsen Nasiri Toosi
    • 2
  • Ali Masoudi-nejad
    • 3
  • Ali Najafi
    • 3
  • Ramin Rahimnia
    • 4
  • Fatemeh Asgari
    • 1
  • Alireza Namazi Shabestari
    • 5
  • Gholamreza Hassanpour
    • 6
  • Seyed-Moayed Alavian
    • 7
  • Freshteh Asgari
    • 8
  1. 1.Department of Virology, School of Public HealthTehran University of Medical SciencesTehranIran
  2. 2.Department of Internal Medicine, Gastroenterology and Hepatology SectionTehran University of Medical SciencesTehranIran
  3. 3.Institute of Biochemistry and Biophysics and COE in BiomathematicsUniversity of TehranTehranIran
  4. 4.Department of Nano Medicine, School of Advanced Technologies in MedicineTehran University of Medical SciencesTehranIran
  5. 5.Department of Human Resource Management and Organizational DevelopmentTehran University of Medical SciencesTehranIran
  6. 6.Department of Mycology and Parasitology, School of Public HealthTehran University of Medical SciencesTehranIran
  7. 7.Research Center for Gastroenterology and Liver DiseaseBaqiatallah University of Medical SciencesTehranIran
  8. 8.Center for Disease Control, Deputy of HealthMinistry of Health and Medical EducationTehranIran

Personalised recommendations